Eli Lilly Management Host Ixekizumab Phase II Psoriasis Data Conference Call (Transcript)

Eli Lilly and Company (LLY)

Ixekizumab Phase II Psoriasis Data Conference Call

April 10, 2012 10:00 am ET

Executives

Philip Johnson -

Eiry Roberts -

Subhashis Banerjee -

Michael Overdorf -

Analysts

Salim Syed - ISI Group Inc., Research Division

Gregory B. Gilbert - BofA Merrill Lynch, Research Division

Kyle Rasbach

David Risinger - Morgan Stanley, Research Division

Seamus Fernandez - Leerink Swann LLC, Research Division

Alison Yang - Barclays Capital, Research Division

Catherine J. Arnold - Crédit Suisse AG, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Ixekizumab Phase II Psoriasis Data Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Vice President of Investor Relations, Mr. Philip Johnson. Please go ahead.

Philip Johnson

Thank you, Connie. Good morning. Thanks for taking the time and join us for today's call. I'm Phil Johnson, Vice President of Investor Relations.

As you know, the New England Journal of Medicine recently published an article detailing Phase II results in patients with chronic plaque psoriasis treated with our anti-IL-17 monoclonal antibody, ixekizumab. Joining me today to discuss these results and to answer your questions are Dr. Eiry Roberts, Vice President of Product Development in our Bio-Medicines business with responsibility for our Autoimmune portfolio, our Bone-Muscle-Joint portfolio and Liprotamase; Dr. Subhashis Banerjee, Senior Medical Director of our Autoimmune platform and the senior author of ixekizumab NEJM article; Michael Overdorf, Global Brand Development Leader for Autoimmune biologic portfolio; and Ilissa Rassner and Travis Coy from the Investor Relations team.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief